cancer treatment

Cancer treatment encompasses diverse approaches including natural products, conventional therapies, and emerging technologies, alongside significant long-term side effects. Research highlights the exploration of plant-derived substances, as the National Cancer Institute examined 53,000 substances, predominantly plants, for potential efficacy. Specific investigations include Clitoria ternatea by Purnamayanti et al. (2022), artemisinin in clinical trials, and EGCG from green tea, with reviews by Izzo et al. (2025) and Shah and Bashir (2021) emphasizing natural products' roles in drug discovery and therapy. Drug delivery innovations feature alginate hydrogels per Abasalizadeh et al. (2020) and targeted systems for norcantharidin (Zhai et al., 2022). Immunotherapies like PD-1/PD-L1 inhibitors are pivotal, while cellular senescence aids prevention. Other targets include TGF-beta signaling and L-asparaginase variants. However, treatments like chemotherapy, radiotherapy, and biotherapy disrupt sleep-wake cycles and cause cancer-related fatigue as most common long-term effect, neuropathy, cardiotoxicity, bone weakening, hypothyroidism, lymphedema, and psychological issues persisting months or years post-treatment, affecting up to 90% of survivors. Tools like CancerKG.org (Gubanov et al., 2024) aid optimal care.

Cancer treatment encompasses therapies such as chemotherapy and radiation that, while aimed at combating malignancy, frequently result in a range of long-term side effects. These include peripheral neuropathy which may be permanent, lymphedema emerging years later, fertility problems varying by treatment type, changes to sexual function and body image from physical alterations like scars or steroids [](/facts/8d77ee43-4846-499b-98ba-d12b0836e1b4), and increased risk of secondary cancers like leukemia post-chemotherapy. Cardiovascular issues such as coronary artery disease and psychological effects like post-traumatic stress [](/facts/ab2c99c3-89be-4f4c-8bde-28c302ed1d0c) or emotional concerns can persist years after treatment, with severity influenced by dosage, duration, and patient factors [](/facts/06bd80f6-77e4-4b62-8a4a-ed8ed5129805). Management strategies include heart-healthy diets for cardiac side effects and fertility preservation methods pre-treatment. Resources like LIVESTRONG for fertility decisions [](/facts/9ad8001e-bed9-47b1-ad84-06a06e7fd39f), CancerCare support groups post-treatment [](/facts/f4e42e33-9e14-415b-9f77-1261843acbe2), Cook For Your Life for taste changes [](/facts/de186c13-ecd3-478c-986c-a9434009464c), and American Dental Association guidance on dental health assist survivors. Emerging approaches aim to mitigate these issues: personalized medicine optimizes response while minimizing sides, targeted therapies like monoclonal antibodies reduce side effects, and innovations such as AI integration, smart drug delivery [](/facts/a6537ce5-0956-46b5-a85e-1aa2204797e8), synthetic lethality [](/facts/ecb8c972-47ca-4947-b18d-29e72be1bc59), and DZ-002 fluorescent chemotherapy promise enhanced precision. A study in BMC Cancer on breast cancer patients, approved by Guangdong Provincial People’s Hospital Ethics Committee and following Helsinki standards, examined treatment impacts on psychology and quality of life [](/facts/31e170bbbf-9505-497b-b456-b920beb4f122). As of recent data, over 15.5 million US survivors exist, projected to rise significantly [](/facts/e9c2439b-d2e5-42da-aea9-5654a2f53354).

Cancer treatment features advancing targeted therapies, particularly synthetic lethality approaches using small molecule compounds, as updated in the European Journal of Medicinal Chemistry (2024), with clinical applications reviewed in Biomedicine & Pharmacotherapy (2024). This field emphasizes cellular mechanisms and clinical translation, according to claim synthetic lethality advancing. Key targets include ATR inhibitors under research, WEE1 kinase per Mueller and Haas-Kogan (2015), and DNA damage response inhibitors, whose history and future are outlined by Drew Y, Zenke FT, and Curtin NJ in Nature Reviews Drug Discovery (2025). Additionally, Wei et al. (2011) link ERK modulation of DNA damage response to MEK inhibitors' role.